| Literature DB >> 18270557 |
Xinhua Yu1, Dirk Koczan, Anna-Maija Sulonen, Denis A Akkad, Antje Kroner, Manuel Comabella, Gianna Costa, Daniela Corongiu, Robert Goertsches, Montserrat Camina-Tato, Hans-Juergen Thiesen, Harald I Nyland, Sverre J Mørk, Xavier Montalban, Peter Rieckmann, Maria G Marrosu, Kjell-Morten Myhr, Joerg T Epplen, Janna Saarela, Saleh M Ibrahim.
Abstract
BACKGROUND: Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin effect in multiple sclerosis (MS) susceptibility. METHODS ANDEntities:
Mesh:
Substances:
Year: 2008 PMID: 18270557 PMCID: PMC2217590 DOI: 10.1371/journal.pone.0001530
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Associations between mtDNA polymorphisms and susceptibility to MS in three European cohorts
| SNP | Gene | Spain | Norway | Germany I | Pooled | ||||||||||||||
| Frequency | OR | 95% CI | P | Frequency | OR | 95% CI | P | Frequency | OR | 95% CI | P | OR | 95% CI | P | |||||
| Patient (n = 417) | Control (n = 510) | Patient (n = 390) | Control (n = 190) | Patient (n = 285) | Control (n = 382) | ||||||||||||||
| 1719 G/A | 16S rRNA | 0.036 | 0.029 | 1.23 | 0.55–2.73 | 0.581 | 0.077 | 0.074 | 1.05 | 0.52–2.19 | 1 | 0.035 | 0.039 | 0.89 | 0.35–2.15 | 0.839 | 1.06 | 0.70–1.01 | 0.875 |
| 4216 T/C | ND1 H/Y | 0.177 | 0.137 | 1.36 | 0.93–1.97 | 0.101 | 0.215 | 0.158 | 1.46 | 0.91–2.40 | 0.119 | 0.228 | 0.230 | 0.98 | 0.67–1.44 | 1 | 1.22 | 0.99–1.53 | 0.078 |
| 9055 G/A | ATP6 A/T | 0.082 | 0.075 | 1.10 | 0.66–1.84 | 0.712 | 0.062 | 0.079 | 0.77 | 0.37–1.61 | 0.481 | 0.060 | 0.055 | 1.09 | 0.53–2.22 | 0.866 | 1.00 | 0.72–1.41 | 0.952 |
| 10398 A/G | ND3 T/A | 0.211 | 0.178 | 1.23 | 0.88–1.73 | 0.241 | 0.200 | 0.205 | 0.97 | 0.62–1.53 | 0.912 | 0.147 | 0.139 | 1.07 | 0.67–1.70 | 0.822 | 1.11 | 0.89–1.39 | 0.377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 16189 T/C | D-loop | 0.119 | 0.139 | 0.84 | 0.56–1.26 | 0.433 | 0.105 | 0.079 | 1.37 | 0.72–2.74 | 0.370 | 0.133 | .0115 | 1.18 | 0.72–1.93 | 0.477 | 1.03 | 0.79–1.35 | 0.852 |
| 16223 C/T | D-loop | 0.160 | 0.171 | 0.89 | 0.62–1.29 | 0.592 | 0.153 | 0.184 | 0.81 | 0.50–1.32 | 0.403 | 0.123 | 0.141 | 0.85 | 0.52–1.37 | 0.565 | 0.86 | 0.68–1.09 | 0.236 |
| Haplogroup | |||||||||||||||||||
| I | 0.017 | 0.016 | 1.07 | 0.33–3.41 | 1 | 0.023 | 0.037 | 0.62 | 0.20–1.99 | 0.418 | 0.014 | 0.021 | 0.66 | 0.15–2.51 | 0.570 | 0.77 | 0.42–1.43 | 0.499 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| K | 0.062 | 0.063 | 0.99 | 0.56–1.75 | 1 | 0.043 | 0.042 | 1.04 | 0.41–2.83 | 1 | 0.021 | 0.037 | 0.57 | 0.18–1.59 | 0.262 | 0.90 | 0.60–1.35 | 0.688 | |
meta-analysis for pooled sample were performed using Mantel-Haenszel test. Halpogroups I, K and J were constructed with 10398G-1719A, 10398G-9055A and 10398G-13708A respectively.
Figure 1Two mtDNA haplotypes associated with MS. (A) Evaluation of the association between four mtDNA haplotypes and MS.
The four haplotypes were constructed with nt13708 G/A and nt4216 T/C polymorphisms. The association was evaluated using the wildtype haplotype (nt13708G-nt4216T) as the control genotype, and Odds ratios and P values of the other three haplotypes were determined. (B) Phylogenetic tree of the two disease-associated mtDNA hyplotypes. The phylogenetic tree were constructed base on the mtDNA sequence of 24 sample with nt13708A-nt4216C (sample A1–A24) and 23 samples with nt13708A-nt4216T (sample B1–B23) using ClusterW softeware.
mtDNA variations linked to in nt13708A variant
| Variations | Gene | Frequency in haplotype nt13708A-nt4216C | Frequency in haplotype nt13708A-nt4216T |
| 73 a/g | Control region | 14/24 | 4/23 |
| 185 g/a | Control region | 7/24 | 0/23 |
| 195 t/c | Control region | 6/24 | 5/23 |
| 228 g/a | Control region | 12/24 | 0/23 |
| 295 c/t | Control region | 23/24 | 0/23 |
| 489 t/c | Control region | 23/24 | 0/23 |
| 1438 g/a | 12S rRNA | 0/24 | 9/23 |
| 2706 a/g | 16S rRNA | 23/24 | 7/23 |
| 3010 g/a | 16S rRNA | 19/24 | 3/23 |
| 4216 t/c | Mt-ND1 Y-H | 24/24 | 0/23 |
| 4769 g/a | Mt-ND2 syn | 0/24 | 9/23 |
| 7028 c/t | Mt-COI syn | 23/24 | 7/23 |
| 10398 a/g | Mt-ND3 T-A | 23/24 | 0/23 |
| 11251a/g | Mt-ND4 syn | 23/24 | 0/23 |
| 11719 g/a | Mt-ND4 syn | 23/24 | 4/23 |
| 12612 a/g | Mt-ND5 syn | 23/24 | 0/23 |
|
|
|
|
|
| 14766 c/t | Mt-CYB T-I | 23/24 | 4/23 |
| 14798 t/c | Mt-CYB F-L | 17/24 | 0/23 |
| 15452 c/t | Mt-CYB L-I | 23/24 | 0/23 |
| 16069 c/t | Control region | 23/24 | 0/23 |
| 16126 t/c | Control region | 23/24 | 0/23 |
| 16519 t/c | Control region | 1/24 | 9/23 |
Positions of variations are according to the reference sequence J01415. Only those variations with frequencies of more than 20% in the total 50 sequenced samples are presented.
Population demographics of the non-well matched MS cohorts
| Cohorts | Patients | Controls | |||||
| Number | Age (mean±SD) | Location | Number | Age (mean±SD) | Location | Composition | |
| Finland | 936 | 42.9±10.0 | Finland | 970 | 63.1± 12.4 | Finland | Unrelated controls |
| Father of controls | |||||||
| Father of patients | |||||||
| Germany II | 342 | 38.1±10.5 | Bochum | 371 | 43.7±12.4 | Essen | Unrelated controls |
| Sardinia | 194 | 37.8±10.2 | Sardinia | 194 | 62.5±15.5 | Sardinia | Father of the patient |
The samples of the Finnish cohort have been collected from five university and central hospitals around Finland (Helsinki, Tampere, Seinäjoki, Kuopio, Oulu).
, calculated from 700 samples with age infomation.
, significantly higher than patients.
Non-significant association of nt13708A variant with MS in three cohorts
| Frequency | OR (95% CI) | ||
| Patient | Control | ||
| Finland | 0.068 (n = 936) | 0.059 (n = 980) | 1.18 (0.75–1.95) |
| Germany II | 0.137 (n = 342) | 0.132 (n = 371) | 1.04 (0.67–1.61) |
| Sardinian | 0.165 (n = 194) | 0.134 (n = 194) | 1.27 (0.72–2.23) |
cases and controls are not age matched and
cases and controls are not geographic matched.
Association of nt13708A variant with MS in Finnish sub-cohorts
| Finland I | Finland II | |||||
| Frequency | OR (95% CI) | Frequency | OR (95% CI) | |||
| Patient | Control | Patient | Control | |||
| Non-age matched, controls younger | - | - | - | 0.059 (n = 730) | 0.033 (n = 122) | 1.84 (0.65–5.19) |
| Non-age matched, controls older | 0.102 (n = 206) | 0.071 (n = 435) | 1.48 (0.83–2.64) | 0.059 (n = 730) | 0.056 (n = 413) | 1.06 (0.63–1.77) |
, Southern Ostrobothnia region;
, Finland except Southern Ostrobothnia region.
, the controls in Finland II cohort consist of 122 unrelated controls.
For the Finland I cohort, the controls consists of 70 fathers of the patients (69.1± 11.0 years) and 365 unrelated controls (59.7±18.7 years) which are significantly higher than patients (46.3±11.7 years). For the Finland II cohort, controls consist of 295 fathers of the patients (66.8±9.5 years) and 108 fathers of the unrelated controls.
Figure 2The prevalence of the nt13708 G/A polymorphism in Caucasian populations.
The data are collected form 19 Caucasian population, including 6 published (closed square), 8 in this study (closed cycle) and 5 unpublished (open cycle). The locations are indicated on the map for the European populations. For the three USA populations, the location were indicated as the text. The prevalence of the mutation are presented as the percentage of the minor allele.